Cord Blood News Volume 6.35 | Sep 11 2014

Influence of Nuclear Blebs and Micronuclei Status on the Growth Kinetics of Human Mesenchymal Stem Cells
Investigators examined the frequency of nuclear blebs (NBs) and micronuclei (MNs) in mesenchymal stem cells (MSCs) from umbilical cord and placenta and found a difference in the number of NBs and MNs depending on the source of the MSCs. [J Cell Physiol] Abstract

Amniotic Fluid Stem Cells Prevent Follicle Atresia and Rescue Fertility of Mice with Premature Ovarian Failure Induced by Chemotherapy
Investigators isolated amniotic fluid stem cells (AFSCs) from transgenic mice that ubiquitously express enhanced green fluorescence protein. These AFSCs exhibited morphologies, immunophenotypes, and mesoderm trilineage differentiation potentials similar to mesenchymal stem cells. [PLoS One] Full Article

Outcomes and Management Strategies for Graft Failure after Umbilical Cord Blood Transplantation
Graft failure is more prevalent after umbilical cord blood transplantation (UCBT) compared to conventional adult stem cell sources. Investigators identified 21 consecutive patients who experienced graft failure after UCBT at their center describe their treatment strategies and outcomes. [Am J Hematol] Abstract

Superselective Intra-Arterial Umbilical Cord Blood Administration to BM in Experimental Animals
The authors investigated whether umbilical cord blood (UCB) could be administered safely using superselective intra-arterial injection. They injected human UCB into the aorta in rats, into the iliac artery in mice and into the femoral nutrient artery in rabbits. [Bone Marrow Transplant] Full Article

Priming Wharton’s Jelly-Derived Mesenchymal Stromal/Stem Cells with ROCK Inhibitor Improves Recovery in an Intracerebral Hemorrhage Model
A strategy of priming mesenchymal stromal/stem cells (MSCs) with fasudil, a Rho-kinase inhibitor, was investigated using Wharton’s jelly-derived MSCs to improve recovery in a rat model of intracranial hemorrhage. [J Cell Biochem] Abstract

Improved Differentiation of Umbilical Cord Blood-Derived Mesenchymal Stem Cells into Insulin-Producing Cells by PDX-1 mRNA Transfection
Investigators aimed to establish a new method to induce PDX-1 expression in mesenchymal stem cells (MSCs) by messenger RNA (mRNA) transfection. MSCs were isolated from human umbilical cord blood and expanded in vitro, with stemness confirmed by surface markers and multipotentiality. [Differentiation] Abstract

Haploidentical Hematopoietic Stem Cell Transplant with Umbilical Cord-Derived Multipotent Mesenchymal Cell Infusion for the Treatment of High-Risk Acute Leukemia in Children
25 children with high-risk acute leukemia received haploidentical hematopoietic stem cell transplant with co-transfusion of umbilical cord multipotent mesenchymal cells. Adverse effects, hematopoietic recovery, complications and outcome were observed during a median follow-up of 12.8 months. [Leuk Lymphoma] Abstract

BMP-7 Improved Proliferation and Hematopoietic Reconstitution Potential of Ex Vivo Expanded Cord Blood-Derived CD34⁺ Cells
The effects of bone morphogenetic protein (BMP)-2 and BMP-7 at different doses on expansion, clonogenicity and differentiation of cord blood-derived CD34⁺ cells were investigated in serum-free medium supplemented with stem cell factor, thrombopoietin and flt3-ligand. [Hum Cell] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. announced dosing of the first patient in a Phase I trial for a second indication of its BL-8040 cancer therapy platform, as a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation, where they can be harvested for transplant supporting the treatment of hematological indications. [BioLineRx Ltd.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania)

Postdoctoral Fellow – Signaling in Hematopoiesis & Leukemia (Albert Einstein College of Medicine of Yeshiva University)

Research Assistant – Ex Vivo Cord Blood Expansion (MD Anderson Cancer Center)

Postdoctoral Positions – Hematopoietic and Induced Pluripotent Stem Cells (Indiana University School of Medicine)

Postdoctoral Positions – Hematologic Malignancies and Cellular Therapy (Duke University Department of Medicine)

Postdoctoral Fellowship – Developing Applications of Mesenchymal Stromal/Stem Cells in Hematopoietic Cell Transplantation (The Research Institute at Nationwide Children’s Hospital)

Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Cord Tissue Processing Technician (Cord Blood Registry)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.